TGR-1202 Tosylate

Modify Date: 2024-01-09 07:48:47

TGR-1202 Tosylate Structure
TGR-1202 Tosylate structure
Common Name TGR-1202 Tosylate
CAS Number 1532533-72-4 Molecular Weight 743.75100
Density N/A Boiling Point N/A
Molecular Formula C38H32F3N5O6S Melting Point 138 - 141 °C
MSDS N/A Flash Point N/A

 Use of TGR-1202 Tosylate


Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach[1][2][3][4].

 Names

Name TGR-1202 Tosylate
Synonym More Synonyms

 TGR-1202 Tosylate Biological Activity

Description Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach[1][2][3][4].
Related Catalog
Target

PI3Kδ:6.2 nM (Kd)

CKIϵ:180 nM (Kd)

PI3Kγ:1400 nM (Kd)

PI3Kβ:>10000 nM (Kd)

PI3Kα:>10000 nM (Kd)

In Vitro Umbralisib tosylate causes a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM[3]. Umbralisib tosylate (10 nM-100 μM) inhibits phosphorylated AKT at Ser473 in a concentration-dependent manner in human lymphoma and leukemia cell lines[4]. Umbralisib tosylate (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells[4].
In Vivo Umbralisib tosylate (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25 in a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line[4].
References

[1]. Maharaj K, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul 14;4(13):3072-3084.

[2]. Burris HA 3rd, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496.

[3]. Swaroop Vakkalankaa, et al. Inhibition of PI3Kδ kinase by a selective, small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth.

[4]. Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99.

 Chemical & Physical Properties

Melting Point 138 - 141 °C
Molecular Formula C38H32F3N5O6S
Molecular Weight 743.75100
Exact Mass 743.20300
PSA 171.81000
LogP 9.56640

 Synonyms

TGR-1202 p-Tosylate
TGR-1202 4-methylbenzenesulfonate
(S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 4-methylbenzenesulfonate
Top Suppliers:I want be here


Get all suppliers and price by the below link:

TGR-1202 Tosylate suppliers

TGR-1202 Tosylate price